Efinaconazole: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Malaysia prescribing information.

Generic Medicine Info

Indications and Dosage

Topical/Cutaneous
Onychomycosis

Adult: For the treatment of cases caused by Trichophyton rubrum and Trichophyton mentagrophytes: As 10% solution: Apply once daily for 48 weeks.

Contraindications

Hypersensitivity.

Special Precautions

Not for ophthalmic, oral, or vaginal administration. Pregnancy and lactation.

Adverse Reactions

Significant: Local pain, irritation, dermatitis.
General disorders and administration site conditions: Application site vesicles.
Skin and subcutaneous tissue disorders: Ingrown toenail.

Pregnancy Category (US FDA)

Topical: C

Patient Counseling Information

Avoid pedicures, use of nail polish, and application of other nail products during treatment.

Monitoring Parameters

Monitor application site for dermatitis, vesicles, pain, and ingrown toenails.

Action

Description:
Mechanism of Action: Efinaconazole a triazole derivative, is a synthetic azole antifungal agent. It inhibits 14α-demethylase which causes a decrease in ergosterol concentrations in fungal cell membranes leading to diminished cell membrane integrity and eventually, fungal cell death.
Pharmacokinetics:
Absorption: Absorbed systemically after topical application (low concentrations).
Excretion: Elimination half-life: 29.9 hours.

Chemical Structure

Storage

Store between 20-25°C. Protect from heat or flame. Do not freeze.

MIMS Class

Topical Antifungals & Antiparasites

ATC Classification

D01AC19 - efinaconazole ; Belongs to the class of imidazole and triazole derivatives. Used in the topical treatment of fungal infection.

References

Anon. Efinaconazole. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 26/02/2021.

Anon. Efinaconazole. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 26/02/2021.

Buckingham R (ed). Efinaconazole. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 26/02/2021.

Jublia Solution (Bausch Health Companies Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 26/02/2021.

Jublia Topical Solution, 10% w/w (Kaken Pharmaceutical Co., Ltd.). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 26/02/2021.

Disclaimer: This information is independently developed by MIMS based on Efinaconazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com